Literature DB >> 10878287

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

J E Souness1, D Aldous, C Sargent.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10878287     DOI: 10.1016/s0162-3109(00)00185-5

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


× No keyword cloud information.
  52 in total

1.  A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy.

Authors:  Fadia Ali Kamal; Kenichi Watanabe; Meilei Ma; Yuichi Abe; Reyad Elbarbary; Makoto Kodama; Yoshifusa Aizawa
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

Review 2.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

4.  The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells.

Authors:  Roxane Hervé; Thomas Schmitz; Danièle Evain-Brion; Dominique Cabrol; Marie-Josèphe Leroy; Céline Méhats
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

Review 5.  Chronic obstructive pulmonary disease * 12: New treatments for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

6.  Assessing protein-ligand binding modes with computational tools: the case of PDE4B.

Authors:  Gülşah Çifci; Viktorya Aviyente; E Demet Akten; Gerald Monard
Journal:  J Comput Aided Mol Des       Date:  2017-05-22       Impact factor: 3.686

Review 7.  Congenital nephrogenic diabetes insipidus: the current state of affairs.

Authors:  Daniel Wesche; Peter M T Deen; Nine V A M Knoers
Journal:  Pediatr Nephrol       Date:  2012-03-17       Impact factor: 3.714

8.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

9.  Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Authors:  Naga Srinivas Tripuraneni; Mohammed Afzal Azam
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810

10.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Authors:  Qing Huai; Yingjie Sun; Huanchen Wang; Dwight Macdonald; Renée Aspiotis; Howard Robinson; Zheng Huang; Hengming Ke
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.